Dynamic Changes of the Fungal Microbiome in Alcohol Use Disorder

• Published in: Frontiers in physiology 2021-07, Vol.12, p.699253-699253
• Main Authors: Hartmann, Phillipp, Lang, Sonja, Zeng, Suling, Duan, Yi, Zhang, Xinlian, Wang, Yanhan, Bondareva, Marina, Kruglov, Andrey, Fouts, Derrick E, Stärkel, Peter, Schnabl, Bernd
• Format: Article
• Language: English
• Subjects: abstinence; alcohol-associated liver disease; fungi; microbiome; mycobiome; Physiology
• ISSN: 1664-042X; 1664-042X
• DOI: 10.3389/fphys.2021.699253

Alcohol-associated liver disease (ALD) is an important cause of morbidity and mortality worldwide. The intestinal microbiota is involved in the development and progression of ALD; however, little is known about commensal fungi therein. We studied the dynamic changes of the intestinal fungal microbiome, or mycobiome, in 66 patients with alcohol use disorder (AUD) and after 2 weeks of alcohol abstinence using internal transcribed spacer 2 (ITS2) amplicon sequencing of fecal samples. Patients with AUD had significantly increased abundance of the genera , , , , and , and of the species and compared with control subjects. Significantly improved liver health markers caspase-cleaved and intact cytokeratin 18 (CK18-M65) levels and controlled attenuation parameter (CAP) in AUD patients after 2 weeks of alcohol abstinence were associated with significantly lower abundance of the genera , , , , , and the species and . This was mirrored by significantly higher specific anti- immunoglobulin G (IgG) and M (IgM) serum levels in AUD patients in relation to control participants, and significantly decreased anti- IgG levels in AUD subjects after 2 weeks of abstinence. The intestinal abundance of the genus was significantly higher in AUD subjects with progressive liver disease compared with non-progressive liver disease. In conclusion, improved liver health in AUD patients after alcohol abstinence was associated with lower intestinal abundances of and , and lower serum anti- IgG levels. Intestinal fungi might serve as a therapeutic target to improve the outcome of patients in ALD.